Abstract:The objective of this study was to investigate the efficacy and safety of a novel paclitaxel-coated balloon catheter in the treatment of chronic atherosclerotic occlusive disease in femoropopliteal arteries. Patients with peripheral artery occlusive disease undergoing percutaneous transluminal angioplasty were prospectively randomized to novel carrier-free ZENFlow (Zhejiang Zylox Medical Device Co Ltd, Hangzhou, China) paclitaxel drug-coated balloon (DCB) group or plain balloon angioplasty (PBA) group. The primary end point was late lumen loss at 6 months assessed by blinded angiographic core laboratory quantitative analyses. Secondary end points included primary target vessel patency at 12 months, binary restenosis, target lesion revascularization, target vessel revascularization, Rutherford class change, and ankle-brachial index (ABI) at 6 months. There were 192 Chinese patients who were randomized in 15 hospitals (93 to DCB and 99 to PBA). The mean age of patients was 68 years; 71.9% were male, and 50.5% were smokers. No significant differences were identified between the groups in terms of baseline patient demographics, comorbidities, Rutherford class, and ABI. Mean lesion length was 62.5 mm; 12.7% had in-stent restenosis, and 37% of lesions were total occlusion. In total, 23 (12%) patients underwent bailout stenting because of flow-limiting dissection after balloon angioplasty. After 6 months, late lumen loss in the DCB and PBA groups was 0.80 ± 0.71 mm and 1.69 ± 0.87 mm (P < .0001), respectively. Primary target vessel patency rate was significantly higher in the DCB group than in the PBA group (54% vs 31.3%; P = .0091) at 12 months. Target vessel restenosis rate was dramatically lower in the DCB group than in the PBA group (16.3% vs 54.6%; P < .0001), as were target lesion revascularization (8.8% vs 27.1%; P = .052) and target vessel revascularization (11.8% vs 30%; P = .0086) at 6 months. Significant improvement in Rutherford class was found in the DCB group compared with the PBA group (P = .0385). Postoperative ABI was markedly increased in the DCB group than in the PBA group (0.89 ± 0.27 vs 0.78 ± 0.28; P = .0182) after 6 months. There were no definitely device-related deaths or major adverse events in either group. Balloon angioplasty using the ZENFlow DCB catheter is a safe and effective method for the treatment of chronic occlusive lesions in the femoropopliteal artery and can achieve satisfactory early and midterm outcomes compared with regular balloon angioplasty.

Medium-term Result of Drug-Coated Balloon with Paclitaxel in Endovascular Treatment of Femoropopliteal Artery In- Stent Restenosis

Short-term efficacy of paclitaxel -coated balloon in the treatment of femoropopliteal artery disease

Short-Term Outcomes Using a Drug-Coated Balloon for Transplant Renal Artery Stenosis

Mid-term outcome of drug coated balloon in the treatment of femoropopliteal artery disease

Acotec Drug-Coated Balloon Catheter

Drug-Coated Balloon for the Treatment of Femoropopliteal Tosaka Class III In-stent Restenosis Lesions

Long-term lumen area enlarged in coronary in-stent restenosis after the treatment of paclitaxel drug-coated balloon dilatation

Comprehensive clinical outcomes of drug‐coated balloon treatment for coronary artery disease. Insights from a single‐center experience

Two-year results and subgroup analyses of the PEPCAD China in-stent restenosis trial: A prospective, multicenter, randomized trial for the treatment of drug-eluting stent in-stent restenosis.

Outcomes of Drug-Coated Balloon Angioplasty for Isolated Chronic Occlusion of the Popliteal Artery: A Retrospective Single-Institution Study.

A prospective, multicenter, randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis: results from the PEPCAD China ISR trial.

Paclitaxel-coated versus uncoated balloon angioplasty for femoropopliteal artery in-stent restenosis

A Multicenter Randomized Trial Assessing ZENFlow Carrier-Free Drug-Coated Balloon for the Treatment of Femoropopliteal Artery Lesions

A New Drug-Coated Balloon for the Treatment of Superficial Femoropopliteal Artery Disease: 12-Month Results from the IN-DEPT SFA Trial

Survival After Coronary Revascularization With Paclitaxel-Coated Balloons

[Mid- and long-term outcomes and prognostic factors of drug-coated balloon angioplasty for treatment of femoropopliteal long lesions]

Head-to-Head Comparison of 2 Paclitaxel-Coated Balloons for Femoropopliteal Lesions

Drug‐coated balloon therapy for in‐stent restenosis in patients with iliofemoral deep vein thrombosis: A single‐arm observational study

LEA 35. Randomized, Multicenter Trial of ZENFlow Drug-Eluting Balloon in the Treatment of Femoropopliteal Artery Occlusive Disease

Comparison between paclitaxel-coated balloon and standard uncoated balloon in the treatment of femoropopliteal long lesions in diabetics.

Five-Year Safety and Effectiveness of Paclitaxel Drug-Coated Balloons Alone or With Provisional Bare Metal Stenting for Real-World Femoropopliteal Lesions: IN.PACT Global Study Subgroup Analysis